Hybio Pharma Surges 20% After Announcing RWA Token Partnership with KuCoin
View all comments(0)
TradingKey – On Monday, August 4, Chinese pharmaceutical firm Hybio Pharma (SHE: 300199) saw its stock skyrocket 20% intraday, hitting the daily limit before settling around +18%, following news of a strategic partnership with KuCoin, the world’s 9th-largest crypto exchange.

Hybio Pharma Stock Chart – Source: Google
Hybio and KuCoin will co-launch a Real World Asset (RWA) tokenization pilot, focused on the future revenue rights of Hybio’s GLP-1 peptide drug pipeline.
- The token will be backed by Hybio’s proprietary R&D assets, including FDA-approved formulations and next-gen triple receptor agonists
- KuCoin will provide full-stack support: blockchain infrastructure, token issuance, on-chain revenue mapping, and global compliance
This marks China’s first pharmaceutical RWA pilot, aligning with Hong Kong’s evolving virtual asset regulations.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
Nvidia’s Trillion-Dollar Market Value Stock Price Flash Crashes, Intraday Drop Exceeds 4.6%. What Are the Reasons?

SpaceX to IPO in June, How Ordinary Investors Seize the Last Opportunity?

SpaceX IPO Date Moved Up to June 12: What Should Investors Watch? How Can European and Asian Investors Buy SpaceX Shares? What Is the Impact on Broad US Markets?

Palantir Grew Revenue 85% and Raised Full-Year Guidance by 10 Points — So Why Is PLTR Down 26% YTD?

SanDisk Is Up 509% YTD After a 251% Revenue Beat - Is the Pullback to $1,382 a Buying Opportunity?

Tradingkey








Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.